We’re delighted to announce that our wholly-owned subsidiary, Nona Biosciences, has entered into a global license agreement with Pfizer for the global clinical development and commercialization of Nona’s MSLN-targeted antibody-drug conjugate (ADC), HBM9033. This agreement represents a significant milestone in the advancement of our proprietary Harbour Mice® platform and in the innovative field of ADC technology, affirming Nona’s robust capabilities and expertise in antibody discovery and development. The fully human monoclonal antibody (mAb) in HBM9033 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to shedding MSLN (sMSLN) while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb ensures superior potency and safety in various preclinical tumor models with differing MSLN expression levels, positioning HBM9033 as a potential globally best-in-class therapeutic option. This partnership with Pfizer expands our global network of collaborations, reinforcing our commitment to providing cutting-edge technology innovations in therapeutics development and, ultimately, bringing meaningful benefits to patients worldwide. Learn More: https://lnkd.in/eNXhwbT2 #biotechnology #innovation #global #company #antibodydiscovery #technology #therapeutics #antibody #biotech #development
Congratulations!